DMAC
DiaMedica Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.75
+2.90%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -23.1%
- EBIT
- -23.5%
- EPS
- -4.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +39.4%
- EPS
- -11.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -34.1%
- EBIT
- -28.9%
- Net income
- -34.0%
- EPS
- -16.7%
- Free cash flow
- -31.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026